Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Methoxsalen (or Xanthotoxin, 8-methoxypsoralen) sold under the brand name Oxsoralen and Melanocyl among others, is a medication used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to ultraviolet (UVA) light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. Levels of individual patient PUVA exposure were originally determined using the Fitzpatrick scale. The scale was developed after patients demonstrated symptoms of phototoxicity after oral ingestion of methoxsalen followed by PUVA therapy. Chemically, methoxsalen is a derivative of psoralen and belongs to a class of organic natural molecules known as furanocoumarins. They consist of coumarin annulated with furan. It can also be injected and used topically.
Read the full article on WikipediaErythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma Clinical criteria: Treatment Phase: Continuing treatment Patient must have received PBS-subsidised treatment with this drug for this PBS indication, AND Patient must have demonstrated a response to treatment with this drug if treatment is continuing beyond 6 months of treatment for the first time, AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; OR The treatment must be in combination with peginterferon alfa-2a only if used in combination with another drug, AND Patient must be receiving the medical service as described in item 14249 of the Medicare Benefits Schedule. Treatment criteria: Must be treated by a haematologist; OR Must be treated by a medical physician working under the supervision of a haematologist. A response, for the purposes of administering this continuing restriction, is defined as attaining a reduction of at least 50% in the overall skin lesion score from baseline, for at least 4 consecutive weeks. Refer to the Product Information for directions on calculating an overall skin lesion score. The definition of a clinically significant reduction in the Product Information differs to the 50% requirement for PBS-subsidy. Response only needs to be demonstrated after the first six months of treatment
Chronic graft versus host disease Clinical criteria: Treatment Phase: Continuing treatment Patient must have received, at anytime prior to this pharmaceutical benefit within the same treatment episode, both: (i) this drug subsidised through the Initial treatment listing, (ii) the extracorporeal photopheresis-MBS benefit for initial treatment, AND Patient must have demonstrated a response to initial treatment with this drug (administered as part of MBS-subsidised extracorporeal photopheresis treatment) obtained through this drug's 'Initial treatment' PBS-listing for the same treatment episode. Treatment criteria: Must be treated by a haematologist; OR Must be treated by an oncologist with allogeneic bone marrow transplantation experience; OR Must be treated by a medical practitioner working under the direct supervision of one of the above mentioned specialist types, AND Patient must be undergoing concurrent treatment with extracorporeal photopheresis as described in the Medicare Benefits Schedule for this condition, AND Patient must not be undergoing re-treatment through this treatment phase immediately following a relapse - see 'Initial treatment' for resuming treatment following relapse.
“~2 hours”
Working under the parallel aged-care framework? Aged-care equivalent →